Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2014-04-16 Interim / Quarterly Rep…
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 6 pages 216.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly report for entities admitted the basis of commitments.' It contains detailed financial data including consolidated cash flow statements, payments to directors, financing facilities, and notes for the current quarter and year to date. The presence of quarterly financial data and the date reference to the quarter ended 31 March 2014 indicate this is a quarterly financial report. The document is substantive and contains actual financial statements and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2014
2014-04-16 English
Ethics approval for procurement for off-the-shelf treatment 2 pages 192.4KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Regeneus has received ethics approval to collect stem cells for a clinical trial of its osteoarthritis treatment. It discusses the company's plans and product development but does not contain financial data, regulatory filings, or detailed report content. The length is 4318 characters, which is relatively short and typical for a press release. There is no indication that this is an annual report, earnings release, or any other formal financial or regulatory filing. It is an announcement related to clinical trial progress and company development news. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2014-04-07 English
Regeneus partners with Hennessy Research for Kvax 2 pages 203.6KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing a partnership between Regeneus and a US manufacturer for a canine cancer immunotherapy product. It discusses business developments, product details, and future plans but does not contain financial statements, regulatory filings, voting results, or detailed financial data. It is not an earnings release, annual report, or any form of regulatory filing. The content is a corporate announcement about a business partnership and product commercialization, which fits best under the category of a general regulatory announcement or miscellaneous corporate news. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2014-04-03 English
HiQCell Joint Registry Results 2 pages 334.2KB
Regulatory Filings Classification · 95% confidence The document is a press release dated 26 March 2014 from Regeneus Ltd announcing interim results from its Joint Registry tracking patient outcomes for the HiQCell osteoarthritis treatment. It reports patient improvements at 12 months and beyond, with some data at 24 months. The document is relatively short (4632 characters) and focuses on clinical outcome data and registry updates rather than comprehensive financial or operational reporting. It does not contain full financial statements or detailed management analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a regulatory filing, audit report, or earnings release. The content is an announcement of interim clinical results and registry data, which aligns best with a Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories. The document also states the full report will be available on the company website, indicating this is an announcement rather than the full report itself.
2014-03-25 English
RGS to present at Regenerative Medicine Investor Day 2 pages 190.9KB
Investor Presentation Classification · 90% confidence The document is a press release announcing that Regeneus will present at the Regenerative Medicine Investor Day on March 26, 2014. It provides details about the event, the company, and contact information. There is no financial data, no report attached or referenced as being published, and no regulatory filing or certification. The document is an announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP) as it relates to a presentation for investors focusing on company strategy and market position.
2014-03-20 English
Appendix 3B 12 pages 474.7KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) announcement used to notify the market of a new issue of securities, application for quotation of additional securities, and related agreements. It details the number and class of securities issued, issue price, purpose of the issue, and other related information. This type of document is a capital/financing update rather than a full financial report or earnings release. It is not an annual report, interim report, or earnings release, nor is it a regulatory filing or announcement of a report publication. The content clearly matches the description of a Capital/Financing Update (CAP) filing type.
2014-03-18 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.